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Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) was a disease caused by the severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) virus with severe respiratory distress syndrome. SARS-CoV-2 can attack the 
gastrointestinal and liver system. In several studies, elevated levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were reported, ranging from 14% to 53%. The increase of neutrophil to lymphocyte ratio 
(NLR) also increases the risk of mortality in COVID-19. 
AIM: This research wants to study ALT, AST, and NLR as prognostic and predictor in COVID-19.
METHODS: A cross-sectional retrospective study was conducted on COVID-19 patients. The diagnostic criteria are 
based on the recommendations of the Indonesian Ministry of Health. The patient’s blood was examined in a central 
laboratory at the hospital. Data analysis was done using SPSS version 22. 
RESULTS: A total of 126 patients with COVID-19 were included in this study. There are 57 (45.2%) patients having 
abnormal liver test. There was a significant difference in the mean AST and NLR between non-survival and survival 
outcome in COVID-19 patients (82.91 ± 103.82 vs. 40.54 ± 33.59 U/L; p = 0.0001 and 7.42 ± 3.65 vs. 3.47 ± 2.41; 
p = 0.0001). High AST (≥34.5 U/L) and NLR (≥4.7) independently associated with non-survival outcome in COVID-19 
patient with odds ratio 5.31 and 9.49 (1.89–14.95, 95% confidence interval [CI]; p = 0.002 and 3.57–25.22, 95% CI; 
p = 0.0001).
CONCLUSION: This study revealed that high AST and NLR at hospital admission were associated with high mortality 
risk in COVID-19 patients. Therefore, AST and NLR can be a significant prognostic of outcome in COVID-19 patients.
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Introduction
At the end of 2019, it was discovered 
pneumonia caused by the severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) virus in 
Wuhan, China, which was named coronavirus 
disease 2019 (COVID-19). COVID-19 was declared 
a pandemic in the world by the World Health 
Organization (WHO) at the end of March 2020. SARS-
CoV-2 has an almost identical genome sequence 
with SARS-CoV. SARS-CoV-2 can be transmitted 
between humans through close contact and air 
droplets inhalation. So far, COVID-19 has spread in 
215 countries around the world [1], [2].
Viral pneumonia is the primary manifestation 
of COVID-19, which has symptoms such as fever, 
fatigue, dry cough, anosmia, and headache. Lately, 
several studies show that COVID-19 can also attack 
other organs besides the respiratory system, such as 
the gastrointestinal and liver system. This is due to 
the spread of main viral entry, angiotensin-converting 
enzyme 2 (ACE2), which is abundant in other organs 
such as the upper esophagus, enterocytes of the ileum 
and colon, liver, and bile duct cells [3], [4].
The neutrophil to lymphocyte ratio (NLR) is an 
easy test to do, by dividing the absolute count of neutrophils 
by the absolute count of lymphocytes. NLR was reported 
to indicate the inflammatory status of patients. Increased 
NLR was a factor in the risk of mortality from various 
diseases such as cancer, acute coronary syndrome, and 
cerebral hemorrhage. Recent research has also revealed 
that increasing the NLR value also increases the risk of 
mortality in COVID-19 [5], [6], [7].
Liver impairment has also been reported 
as a common manifestation, although it is not a 
prominent feature of the illness. Several studies 
have shown different degrees of elevated serum liver 
biochemistries in COVID-19 patients, mainly indicated 
by abnormal alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels. Recent 
studies have found that SARS-CoV-2 can bind to 
ACE2 in cholangiocytes, which triggers cholangiocyte 
dysfunction and triggers a systemic inflammatory 
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response that ends with liver injury. In several studies, 
elevated levels of ALT and AST were reported, ranging 
from 14% to 53% [8], [9]. It remains unclear whether 
these laboratory test alterations are associated with a 
worse prognosis. This research wants to study ALT, AST, 
and NLR’s comparison of patient outcome and their best 
cut point for outcome prediction in COVID-19 patients.
Methods
Patient selection
This study was a cross-sectional retrospective 
study conducted on COVID-19 patients who had been 
confirmed at Prof. Dr. R.D. Kandou hospital. Inclusion 
criteria are stated as follows: Male or female aged ≥18 
years old, patients were diagnosed with COVID-19. 
From March 1, to June 30, 2020, 145 patients were 
diagnosed with COVID-19 based on the guideline 
for diagnosis and prevention coronavirus 2019 in 
Indonesia. This study was approved by the Local Ethics 
Committee.
Confirmation of COVID-19
The presence of SARS-CoV-2 was detected 
by real-time reverse transcription PCR. Two pairs 
of primers targeting the open reading frame 1ab 
(ORF1ab) and the nucleocapsid protein (N) were 
amplified and examined. The corresponding sequences 
for ORF1ab were 5’-CCCTGTGGGTTTTACACTTAA-3’ 
(F), 5’-ACGATTGTGCATCAGCTGA-3’ (R), and 
5’-CY3-CCGTCTGCGGTATGTGGAAAGGTTATGG-
BHQ1-3’ (probe), and those for N were 
5 ’ - G G G G A A C T T C T C C T G C TA G A AT- 3 ’ ( F ) , 
5’-CAGACATTTTGCTCTCAAGCTG-3’(R), and 
5’-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-
3’(probe). These diagnostic criteria are based on the 
recommendations of the Indonesian Ministry of Health.
Data collection
Medical records from 145 patients were 
collected and examined by researchers. Identity, 
laboratory, and outcome data from patients were 
obtained from the hospital information system. Patient 
outcomes are categorized as survival and non-survival.
NLR, ALT, and AST
The patient serum and peripheral venous 
blood were taken from all COVID-19 patients who were 
confirmed when the patient entered the hospital. The 
patient’s blood was examined in the central laboratory 
at Prof Dr. R.D. Kandou Hospital following the hospital’s 
standard operative procedures. Liver test abnormalities 
were defined as the elevation of AST >40 U/L and 
ALT >40 U/L [9].
Statistical analysis
Data analysis was performed through 
univariate and bivariate analyses using the SPSS 22nd 
version (SPSS Inc., Chicago) with a 95% confidence 
interval (CI). Bivariate analysis was performed using 
Mann–Whitney. Multivariate analysis was performed 
using logistic regression. Data were also analyzed 
using receiver operating characteristic (ROC) curve and 
Youden’s index, p < 0.05 was considered statistically 
significant.
Results
In this study, 145 confirmed COVID-19 patients 
were found, but only 126 patients had complete data. Of 
the total, 126 patients consisted of 60 men (47.6%) and 
66 women (52.4%). A total of 32 (25.4%) patients died 
during hospitalization. The mean age of the patients 
was 48.81 ± 15.70 years. There are 57 (45.2%) patients 
with an abnormal liver test consisted of increasing AST 
(38.1%) and ALT (31%). The baseline characteristics of 
the patients are shown in Table 1. NLR, AST, and ALT 
were higher in non-survival than survival outcomes in 
COVID-19 patients (Table 1).
There was a significant difference in the mean 
AST levels between non-survival and survival outcomes in 
COVID-19 patients. Patients in the non-survival group had 
higher AST levels than the survival group (82.91 ± 103.82 
vs. 40.54 ± 33.59 U/L; p = 0.0001) (Table 1).
There was no significant difference in the mean 
ALT levels between non-survival and survival outcomes 
in COVID-19 patients (56.72 ± 71.71 vs. 34.57 ± 32.28 
U/L; p = 0.136) (Table 1).
There was a significant difference in the mean 
NLR between non-survival and survival outcomes 
Table 1: Basic characteristics of the study population
Characteristics Outcome p
Non-survival Survival
n Min Max Median Mean SD n Min Max Median Mean SD
Age (years) 32 32.00 80.00 58.50 57.31 12.14 94 19.00 82.00 44.00 45.91 15.78 0.0001
NLR 32 1.71 15.17 7.04 7.42 3.65 94 0.70 13.00 2.58 3.47 2.41 0.0001
AST (U/L) 32 21.00 544.00 50.00 82.91 103.82 94 15.00 207.00 30.00 40.54 33.59 0.0001
ALT (U/L) 32 10.00 358.00 30.00 56.72 71.71 94 3.00 198.00 25.00 34.57 32.28 0.136
Min: Minimal; Max: Maximal; SD: Standard deviation; n: Count. NLR: Neutrophil to lymphocyte ratio, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase.
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in COVID-19 patients. Patients in the non-survival 
had NLR significantly higher than the survival group 
(7.42 ± 3.65 vs. 3.47 ± 2.41; p = 0.0001) (Table 1).
Analysis using the ROC test showed that AST 
had an area under the ROC of 0.739 (p = 0.0001), and 
NLR had an area under the ROC of 0.830 (p = 0.0001) 
(Figure 1).
Youden’s index was calculated to determine 
the best AST and NLR cut off point to give better 
sensitivity dan specificity to predict COVID-19 patients’ 
outcome. For AST, the best cutoff point was 34.5 U/L to 
get 78.12% sensitivity and 61.70% specificity, and for 
NLR, the best cutoff point was 4.7 to get 75% sensitivity 
and 79.78% specificity.
Figure 1: ROC curve of AST and NLR
After logistic regression analysis was 
performed, high AST (≥34.5 U/L) and NLR (≥4.7) 
remained independently associated with non-survival 
outcome in COVID-19 patient with odds ratio 5.31 
(1.89–14.95, 95% CI; p = 0.002) and 9.49 (3.57-25.22, 
95% CI; p = 0.0001), respectively (Table 2).
Table 2. Logistic regression analysis of predictors of COVID-19 
patients’ mortality
Variablea OR (95% CI) p
AST (≥34.5 U/L) 5.31 (1.89–14.95) 0.002
NLR (≥4.7) 9.45 (3.57–25.22) 0.0001
CI: Confidence interval; OR: Odds ratio; aadjusted for gender. NLR: Neutrophil to lymphocyte ratio, AST: 
Aspartate aminotransferase
Discussion
In this study, 45.2% of COVID-19 patients had 
abnormal liver tests, where there was an increase in 
AST by 38.1% and ALT by 31%. Fan et al. also found 
that there were abnormal liver tests in 37.1% of patients 
with COVID-19 [10]. This result is almost the same as 
the study conducted by Chen et al., where the increase 
in AST was 35%, and ALT was 28% [11].
Liver impairment is closely related to mortality in 
COVID-19 patients. In this study, it was found that AST 
and ALT values were higher in COVID-19 patients with 
the non-survival group, where statistically, AST levels had 
a significant difference between COVID-19 patients with 
non-survival and survival outcome (p < 0.05). Several 
studies also found that AST increases more frequently 
than ALT in severe COVID-19 patients [12], [13]. A study 
conducted by Lei et al. gave similar results, in which 
patients with elevated AST had a high risk of mortality [14].
Several studies have shown that SARS-CoV-2 
requires ACE2 as a receptor to enter cells, where ACE2 
is mainly expressed in the heart, lungs, and kidneys. In 
addition, ACE2 is also slightly expressed in the colon 
and liver. The previous studies have shown that ACE2 
expression is present in cholangiocytes, suggesting 
that cholangiocyte is the direct target of SARS-CoV-2 
to attack the liver. The increase in AST and ALT is an 
indicator of liver cell damage. However, pathological 
analysis of the liver tissue of COVID-19 patients failed to 
prove that cholangiocyte damage and viral infiltration in 
liver tissue occurred. The specific cause of liver damage 
and elevated liver transaminase enzymes is not clear and 
needs further study [8], [9], [14], [15], [16], [17], [18], [19].
In this study, it was found that there was an 
increase in NLR in COVID-19 patients with the non-
survival outcome, which was statistically significant 
when compared with COVID-19 patients with survival 
outcome (p < 0.05). Liu et al. also obtained the same 
results, where a higher increase in NLR was associated 
with an increased risk of mortality in COVID-19 
patients [7] Research conducted by Yan et al. also 
found the same thing [20].
NLR is an easy method to evaluate the systemic 
inflammatory response, where the NLR is calculated 
by taking the neutrophil and lymphocyte values into 
account. Neutrophils play an important role in the innate 
immune response, while lymphocytes play an important 
role in the inflammatory response. The increase in NLR 
results from an inflammatory response that stimulates 
neutrophil production and accelerates the apoptosis of 
inflammatory lymphocytes. Increased neutrophils result 
in increased systemic arginase activity, which depletes 
systemic arginase reserves. Where arginine is a single 
subtract for the formation of nitric oxide (NO), which has 
antiviral activity against RNA viruses such as SARS-
CoV-2. Therefore, an increase in NLR indicates an 
imbalance of the inflammatory response that can result 
in death [7], [20], [21].
Based on the ROC curve analysis, the AST 
and NLR showed the significant performance to predict 
COVID-19 patient’s mortality. The best cut-off point 
for AST and NLR was 34.5 U/L and 4.7. This study 
supports that a high AST (≥34.5 U/L) and NLR (≥4.7) 
are a strong predictor for mortality in patients with 
COVID-19. COVID-19 patients with high AST and NLR 
were 5.31 and 9.49 times more likely to have a non-
survival outcome. However, a scoring system is needed 
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to assess the prognosis of COVID-19. It is hoped that 
the prognosis will be more accurate with scoring system 
so that early treatment can be given.
There are some limitations to this study. First, 
this study was retrospective, and there some cases did 
not have enough data. Second, we did not do multiple 
testing of liver transaminase enzymes and NLR during 
hospitalization. Third, all subjects in this study were 
Manado patients with COVID-19, so this study’s results 
might not directly be applied to other races.
Conclusion
This study revealed that high AST and NLR at 
hospital admission were associated with high mortality 
risk in COVID-19 patients. Therefore, AST and NLR 
can be a significant prognostic of outcome in COVID-19 
patients. However, a scoring system is needed to have 
a more accurate prediction of prognosis.
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